Clinical trials: 5-Fluorouracil
Breast Cancer
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative…
- Trial name
- NCT04031703
- Testing
- Paclitaxel, Carboplatin, Epirubicin
- Volunteers
- 647 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
The purpose of this prospective, randomized, multicenter, controlled clinical study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared to transarterial chemoembolization (TACE) when…
- Trial name
- NCT07594340
- Testing
- Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binkui Li
Colorectal Carcinoma Metastatic in the Liver
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals…
- Trial name
- METEORITE (NCT06555133)
- Testing
- yttrium-90 radioembolization
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Nasopharyngeal Carcinoma
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma
The primary objective of this study is to determine the tolerance and overall survival in patients with stage Ⅲ NPC treated with neoadjuvant chemotherapy and concurrent chemoradiation.
- Trial name
- NCT00816855
- Testing
- docetaxel, cisplatin, fluorouracil
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
- Trial name
- NCT04066543
- Testing
- TACE, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced GI Cancer
Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
This is a Phase I dose escalation trial to assess MTD of MK-3475 in combination with mFOLFOX6 followed by a safety expansion open label, nonrandomized trial with MK-3475 at MTD in combination with mFOLFOX6 and supplemental…
- Trial name
- MK-3475 GI (NCT02268825)
- Testing
- MK-3475
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Utah
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
To learn if atezolizumab in combination with oxaliplatin and 5-fluorouracil (5-FU), when given before surgery, can help to control esophageal and/or gastroesophageal cancer.
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03784326
- Testing
- Atezolizumab, Conventional Surgery, Fluorouracil
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
Breast Cancer
Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer
This study was a prospective, single-arm, open-label phase II clinical trial conducted at National cancer center in China.
- Trial name
- NCT05747326
- Testing
- oral vinorelbine and capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mouth Neoplasms, Carcinoma, Squamous Cell
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial (NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared to the standard treatment.
- Trial name
- NCT02285543
- Testing
- TPF induction chemotherapy, surgery, radiotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Head & Neck Cancer
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
This is an open-label, single arm, multicenter phase 2 study. The study is to evaluate the activity of a combination therapy with nal-IRI (PEP02, MM-398, Onivyde®) plus 5-FU and leucovorin in patients with squamous cell carcinoma…
- Trial name
- NCT03712397
- Testing
- nanoliposomal irinotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 59 people
- Sponsor
- National Health Research Institutes, Taiwan
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Trial design: Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Trial name
- FOLF(HA)iri (NCT01290783)
- Testing
- Irintoecan, HA-Irinotecan solution for Infusion
- Where
- 5 sites in Australia
- Volunteers
- 390 people
- Sponsor
- Alchemia Oncology
Colorectal Neoplasms
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy…
- Trial name
- OrigAMI-3 (NCT06750094)
- Testing
- Amivantamab, Cetuximab, Bevacizumab
- Where
- 251 sites in United States, Australia and 24 more
- Volunteers
- 700 people
- Sponsor
- Janssen Research & Development, LLC
GC/GEJC
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
This is an open-label, dose-escalation and dose-expansion phase Ib/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of HCB101 in combination therapies in subjects with gastric or GEJ…
- Trial name
- HCB101 GC GEJ (NCT07680569)
- Testing
- Zolbetuximab, Oxaliplatin + 5-Fluorouracil/Leucovorin, CAPOX (oxaliplatin/capecitabine)
- Volunteers
- 40 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Gastric Cancer
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine, leucovorin, oxaliplatin, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00448682
- Testing
- Docetaxel, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Gastric Cancer
Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma
The aim of this study is to observe the efficacy, safety, postoperative pathological response rate and survival benefit of immume checkpoint inhibitor PD-1 SHR1210 combined with chemotherapy in neoadjuvant therapy of locally…
- Trial name
- NCT03939962
- Testing
- SHR1210 combined with FOLFOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Pancreatic Cancer
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU)…
- Trial name
- PancVax (NCT02548169)
- Testing
- DC Vaccine + Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Baylor Research Institute
Pancreatic Cancer, PDAC
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 302 (NCT06625320)
- Testing
- RMC-6236, Gemcitabine, nab-paclitaxel
- Where
- 60 sites in United States, France and 5 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This is a multicenter, randomized, controlled, open-label study comparing perioperative atezolizumab with FLOT chemotherapy versus FLOT alone in patients with locally advanced, operable adenocarcinoma of the stomach or GEJ with…
- Trial name
- DANTE (NCT03421288)
- Testing
- Atezolizumab, 5-Fluorouracil, Calciumfolinat
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 677 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Rectal Cancer
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab (Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with standard radiation therapy and capecitabine…
- Trial name
- NCT00543842
- Testing
- Bevacizumab, Capecitabine, Erlotinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.